Objective. To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-tosevere rheumatoid arthritis (RA) who had an inadequate response to MTX.
Objective. To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-tosevere rheumatoid arthritis (RA) who had an inadequate response to MTX.
Methods. In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (n 5 378) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg plus MTX, or matching placebo plus MTX once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12.
Results. ACR20 response rates at week 12 were 43.9%, 61.5% (P < 0.05 versus placebo), 46.4%, 57.7%, and 44.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P < 0.05) and 150 mg (P < 0.01) groups compared with placebo at week 12. Overall, the incidence of adverse events (AEs) was similar between peficitinib and placebo. The most common AEs were urinary tract infection (n 5 22 [6%]), upper respiratory tract infection (n 5 16 [4%]), and diarrhea (n 5 16 [4%]). There were 3 cases of herpes zoster infection (2 in the peficitinib 100 mg group and 1 in the 150 mg group) and 2 cases of serious infection (viral infection in the peficitinib 100 mg group and erysipelas in the 150 mg group).
Conclusion. The ACR20 response rate in the group receiving peficitinib 50 mg plus MTX was significantly different compared with the rate in patients receiving placebo, but there were no apparent dose-dependent responses, and the placebo response rate was high. Peficitinib plus MTX in patients with moderate-to-severe RA was well tolerated, with limited safety signals emerging.
Several proinflammatory cytokines involved in the pathogenesis of rheumatoid arthritis (RA) use the JAK signal transduction pathway to initiate their immune responses (1, 2) . Tofacitinib, a JAK inhibitor with selectivity for JAK-1 over JAK-3 and JAK-2 over Tyk-2 (3), approved for the treatment of RA in several countries (4, 5) , has demonstrated efficacy in the treatment of RA in several trials (6) (7) (8) (9) . Currently, a number of JAK inhibitors are under investigation, including baricitinib (JAK-1 and JAK-2 inhibitors) (10) , filgotinib (JAK-1 inhibitor) (11) , and ABT-494 (JAK-1 inhibitor) (12) . Peficitinib (ASP015K) is an orally administered once-daily JAK inhibitor in development for the treatment of RA (13) . Peficitinib inhibits JAK-1, JAK-2, JAK-3, and Tyk-2 enzyme activities, with 50% inhibition concentration values of 3.9, 5.0, 0.7, and 4.8 nmoles/liter, respectively, and therefore has moderate selectivity for JAK-3 inhibition (13) . The efficacy and safety profile of peficitinib for the treatment of RA has been investigated in 2 other phase II trials. In one phase IIb randomized study assessing the efficacy and safety of peficitinib for the treatment of RA in Japan (ClinicalTrials.gov identifier: NCT01649999), the peficitinib 50 mg, 100 mg, and 150 mg groups demonstrated a significantly greater response rate according to the American College of Rheumatology 20% criteria for improvement (ACR20) (14) at week 12 compared with placebo, with a statistically significant dose response. In the other phase IIb randomized study assessing the use of peficitinib without concomitant methotrexate (MTX) for the treatment of RA, the peficitinib 100 mg and 150 mg groups demonstrated a significantly higher ACR20 response at week 12 compared with placebo, which was achieved as early as week 2 (15) . In both studies, peficitinib was well tolerated over 12 weeks.
Here, we report the findings of a third phase IIb randomized study to evaluate the efficacy, safety, and dose response of orally administered, once-daily peficitinib in combination with MTX over 12 weeks in patients with moderate-to-severe RA who had an inadequate response to MTX.
PATIENTS AND METHODS
Study design. This phase IIb, randomized, doubleblind, parallel-group, placebo-controlled, dose-finding, global, multicenter study of orally administered once-daily peficitinib in patients with moderate-to-severe RA with an inadequate response to MTX (ClinicalTrials.gov identifier: NCT01554696) was conducted at 43 sites in 8 countries (US [16 locations The trial was conducted over 12 weeks, during which patients were seen at baseline and at weeks 1, 2, 4, 8, and 12. Screening visits were performed up to 4 weeks prior to baseline, and patients who completed the 12-week study were offered participation in a long-term, open-label extension study. If patients did not participate in the extension study, they were followed up for 30 days.
Patients were randomly assigned at a 1:1:1:1:1 ratio to receive, in combination with a weekly dose of MTX, either peficitinib 25 mg, 50 mg, 100 mg, or 150 mg, or matching placebo. The investigator, patient, clinical staff, and sponsor were blinded with regard to treatment assignments. Patients were stratified by geographic region (Europe [Belgium, Bulgaria, Czech Republic, Hungary, and Poland], Latin America [Colombia and Mexico], or North America [US]) and by prior anti-tumor necrosis factor (anti-TNF) use (,25% of the randomized patients were allowed to have received an anti-TNF agent).
An independent ethics committee or institutional review board reviewed the ethical, scientific, and medical appropriateness of the study before it was conducted. Independent ethics committee/institutional review board approval of the protocol, informed consent, and patient information were obtained prior to the authorization of a drug shipment to a study site. Changes to the protocol, made after the initiation of study enrollment, are described in Supplementary Materials (17) and to have active RA as defined by a tender joint count (TJC) in 28 joints of $6, a swollen joint count (SJC) in 66 joints of $6, and a C-reactive protein (CRP) level of $0.8 mg/dl (normal range ,1.0 mg/dl) (18) or an erythrocyte sedimentation rate (ESR) of $28 mm/hour. Patients must have continued to meet the joint count criteria at the baseline visit, prior to randomization.
Patients who had taken any of the following diseasemodifying antirheumatic drugs (DMARDs) or biologic agents within the following periods prior to the first study drug dose were excluded: gold, azathioprine, and penicillamine (28 days); etanercept (28 days); certolizumab, adalimumab, golimumab, and infliximab (60 days); cyclophosphamide (180 days); leflunomide (60 days; if the patient had undergone a cholestyramine washout, then the period was reduced to 30 days prior to day 1 dosing). Patients were also excluded if they previously used a non-anti-TNF biologic DMARD (e.g., anakinra, abatacept, any CD20 inhibitor, or tocilizumab) or had previous intolerance to JAK inhibitors. A patient was also excluded if he or she had Mycobacterium tuberculosis infection (and was not receiving antimicrobial therapy according to local guidelines), abnormal chest radiograph, virus vaccination within 30 days prior to the first dose of study drug, hepatitis B, hepatitis C, HIV, any other autoimmune rheumatic disease other than Sj€ ogren's syndrome, clinically significant infections, or any malignancy except successfully treated basal or squamous cell carcinoma or in situ carcinoma of the cervix.
Concomitant medications. The only permitted concomitant medications for RA other than MTX were nonsteroidal antiinflammatory drugs, hydroxychloroquine (#400 mg/day), chloroquine (#250 mg/day), sulfasalazine (#3 gm/day), and/or oral corticosteroids (prednisone or equivalent [#10 mg/day]). Changes in the MTX dose or in the route of administration within 28 days prior to the first dose of study drug, or any time during the study, were prohibited. The dose may have been reduced for safety. 710 KIVITZ ET AL Study end points. The primary end point was the percentage of patients achieving an ACR20 response using the CRP level at week 12. Secondary and other end points included the percentage of patients who met the ACR 50% criteria for improvement (ACR50 response) or the ACR 70% criteria for improvement (ACR70 response) at week 12, change from baseline in the Disease Activity Score in 28 joints using the CRP level (DAS28-CRP) (19) at week 12, and change from baseline in the Clinical Disease Activity Index (CDAI) (20) at week 12.
Safety and laboratory assessments. Safety was assessed via adverse event (AE) reporting (coded using Medical Dictionary for Regulatory Activities version 14.0) (21), vital signs, clinical laboratory evaluations (hematology, chemistry, urinalysis, and fasting lipid profile), 12-lead electrocardiograms, and physical examinations. AE grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Sample size determination. The planned sample size was 375 patients. Assuming ACR20 response rates of 55% for any peficitinib group and 30% for the placebo group, 75 patients per treatment group (adjusted for an expected 10% withdrawal rate) were needed to reach 80% power to detect a difference between any of the peficitinib groups and placebo using a 2-sided continuitycorrected chi-square test with a significance level of 5%.
Statistical analysis. The full analysis set consisted of all patients who were randomized and received at least 1 dose of peficitinib. This was the primary data set used for efficacy analyses. Initial analysis of the primary and secondary end points was based on a logistic regression model with effects for treatment group, prior treatment with an anti-TNF agent, and geographic region. Missing ACR responses were imputed using nonresponder imputation. If not all ACR responses were missing, the missing values were first imputed using the last observation carried forward (LOCF) approach at week 12, and then the ACR response rate was calculated.
Additional analyses using normal approximation to the binomial distribution were also conducted. An analysis of covariance model with fixed effects for treatment group, prior treatment with an anti-TNF agent, geographic region, and baseline score as covariates was used for the secondary end point of change from baseline in the DAS28-CRP; for the DAS28, missing component values were imputed using the LOCF method. A mixed-effects model for repeated measures was used for the analysis of change from baseline in the CDAI, with the patient as a random effect. Stratification by geographic region was excluded from the model if not significant (P , 0.01). Within-patient variance-covariance was estimated using an unstructured covariance matrix. No adjustments for multiplicity were performed in these analyses. The safety analysis set was defined as all patients who received at least 1 dose of peficitinib.
RESULTS

Patients.
A total of 548 patients were screened for inclusion, of whom 379 were randomized (peficitinib 25 mg Demographic characteristics and baseline disease activity were similar across the study arms (Table 1) . In a predominantly female population (;83%), the mean age ranged from 52.3 years to 54.5 years across the study arms, 23-33% of patients were Hispanic or Latino, and the mean duration of RA was 7.2 -8.1 years. The baseline MTX dose was similar across the study arms, and the median duration of MTX treatment prior to baseline was 78.5 weeks. 
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Efficacy. The primary end point of an ACR20 response at week 12 was achieved by 43.9%, 61.5%, 46.4%, 57.7%, and 44.4% of patients in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively ( Figure  2A) . A statistically significant difference in the ACR20 response rate versus placebo was observed for peficitinib 50 mg (P , 0.05) at week 12. ACR50 response rates at week 12 were 18.2%, 33.3%, 33.3%, 37.2%, and 26.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. No statistically significant differences in the ACR50 and ACR70 response rates versus placebo were observed for any peficitinib treatment group at week 12.
When the analysis was stratified by geographic region, in Europe, statistically significant differences (P , 0.05) in the percentage of patients achieving ACR20 responses at week 12 were seen in the peficitinib 100 mg and 150 mg groups compared with placebo (53.8% and 56.3%, respectively, versus 28.1%) ( Figure 2B ). In North America and Latin America, there were no statistically significant differences between any peficitinib group and 
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placebo ( Figure 2B ). In these regions, higher-thanexpected placebo response rates were observed. When Latin America was excluded from the analysis, the peficitinib 50 mg and 150 mg groups showed a statistically significant ACR20 response compared with placebo (56.9% and 58.5%, respectively, versus 38.3%; P < 0.05) ( Figure 2C ). Overall, ACR20 response rates increased over time ( Figure 3A) . The mean DAS28-CRP decreased from baseline over time in all study arms ( Figure 3B ). There was a statistically significant difference in the mean change in the DAS28-CRP between baseline and week 1 in patients in the peficitinib 50 mg and 150 mg groups versus placebo (P , 0.01), which was maintained throughout the 12-week trial in the peficitinib 150 mg group. The difference between the peficitinib 50 mg group and the placebo group was significant at week 1 (P , 0.01), week 2 (P , 0.05), and week 12 (P , 0.05). At week 12, there was a statistically significant difference in the DAS28-ESR in the peficitinib 50 mg and 150 mg groups versus placebo (P , 0.05 and P , 0.01, respectively), which was reported as early as week 1 ( Figure 3C ). At week 12, a statistically significant proportion of patients achieved a decrease in the CRP level and the ESR, respectively, in the peficitinib 50 mg (P , 0.001 and P , 0.01), 100 mg (P , 0.05 and P , 0.001), and 150 mg (P , 0.001 and P , 0.001) groups compared with placebo ( Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.39955/abstract).
A total of 100 patients (26%) had been exposed to an anti-TNF treatment prior to study initiation (Figure 4) , and there were no statistically significant differences in terms of ACR20 responses between any peficitinib group and placebo, when stratified by prior treatment with an anti-TNF agent. Placebo response rates were similar in both the anti-TNF-experienced and anti-TNF-naive groups (42.1% and 45.3%, respectively) ( Figures 4A and B) .
Analysis of the individual ACR components revealed no mean difference from baseline to week 12 between any peficitinib group and placebo for the TJC in 68 joints, the SJC in 66 joints, or the Health Assessment Questionnaire disability index (22) assessments (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39955/abstract). Dose-dependent decreases in physician's global assessment, subject's global assessment, subject's global assessment of arthritis pain, CRP, and ESR were observed with peficitinib. There was a statistically significant difference between the peficitinib 150 mg group and placebo (P , 0.05) for the least squares mean CDAI at week 12 ( Supplementary Figure 2 , available on the Arthritis Figure 3 . ACR20 response rates (A) and changes in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (B) and the DAS28 using the erythrocyte sedimentation rate (DAS28-ESR) (C) from baseline to week 12. In A, P , 0.05 for the peficitinib 25 mg, 50 mg, and 100 mg groups and P , 0.01 for the 150 mg group at week 2; P , 0.05 for the 50 mg group at weeks 4, 8, and 12. In B, P , 0.01 for the peficitinib 50 mg and 150 mg groups at week 1; P , 0.05 for the 50 mg group and P , 0.01 for the 150 mg group at week 2; P , 0.05 for the 150 mg group at weeks 4 and 8; P , 0.05 for the 50 mg group and P , 0.01 for the 150 mg group at week 12. In C, P , 0.05 for the peficitinib 50 mg group and P , 0.01 for the 150 mg group at weeks 1 and 2; P , 0.01 for the 150 mg group at week 4; P , 0.05 for the 150 mg group at week 8; P , 0.05 for the 50 mg group and P , 0.01 for the 150 mg group at week 12. See Figure 2 [3%] ). The majority of AEs (97%) were mild or moderate in severity, with a total of 3 serious AEs (SAEs) (1 case of erysipelas in the 150 mg group, 1 viral infection in the 100 mg group, and 1 pulmonary mass in the 100 mg group); no deaths were reported during this study ( Table 2) . Two of the 3 SAEs (viral infection and pulmonary mass) led to treatment discontinuation. The pulmonary mass, which was not considered to be drug related, occurred in a 65-year-old white female patient who was a smoker, and randomized to the peficitinib 100 mg group, but discontinued treatment on study day 64, and the study 18 days later (the event was ongoing at the time of study discontinuation). No biopsy of the pulmonary mass was performed, nor was treatment given for the event. Positron emission tomography of the chest revealed that the pulmonary mass was most likely due to postinflammatory changes. There were 3 cases (1%) of herpes zoster (2 grade 1 events in the peficitinib 100 mg group, and 1 grade 2 event in the peficitinib 150 mg group, none of which disseminated).
Dose-dependent decreases in the mean absolute neutrophil count, white blood cell count, and platelet count from baseline to week 12 were reported in the peficitinib groups. One patient (1.3%) in the peficitinib 50 mg group had a shift from baseline in the absolute neutrophil count to 1,000 cells/ml to ,1,500 cells/ml at week 12. Two patients (1 in the peficitinib 50 mg group and 1 in the peficitinib 150 mg group) experienced neutropenia to ,1,500 cells/ml (leading to treatment discontinuation for the patient in the 150 mg group), and 1 patient (1.3%) in the peficitinib 50 mg group experienced a grade $2 decrease in the absolute neutrophil count at week 12. No patient had a shift from baseline in the white blood cell count at week 12, and 1 patient (1.3%) in the peficitinib 50 mg group experienced a grade $2 decrease in the white blood cell count at week 12. One patient (1.2%) in the peficitinib 100 mg group had a shift from baseline of 200 cells/ml to ,500 cells/ml in the absolute lymphocyte count at week 12.
Dose-dependent increases in the mean hemoglobin, creatine phosphokinase (CPK), creatinine, and highdensity lipoprotein (HDL) levels from baseline to week 12 were reported in the peficitinib groups. Lipid ratios (HDL:low-density lipoprotein [LDL] and HDL:total cholesterol) remained stable in all treatment groups throughout the 12-week study. Six patients (2 in the placebo group, 3 in the peficitinib 25 mg group, and 1 in the peficitinib 100 mg group) had a shift from baseline to the prespecified range of 8.0 to ,10.0 gm/dl for hemoglobin at week 12, and 6 patients (2 in the placebo group, 3 in the peficitinib 25 mg group, and 1 in the peficitinib 100 mg group) experienced grade $2 anemia. Two patients (1 in the peficitinib 50 mg group and 1 in the peficitinib 150 mg group) had a shift from baseline in the CPK level to .23 the upper limit of normal (ULN) -#53 ULN at week 12. No patient had a shift from baseline in the creatinine level, and there were no grade $2 shifts. At week 12, the mean change from baseline in the alanine transaminase (ALT) and aspartate transaminase (AST) levels remained stable in the placebo group and all peficitinib groups except the peficitinib 150 mg group, in which the mean ALT and AST levels increased. No patient had shifts from baseline in the 
DISCUSSION
In this study comparing 4 peficitinib doses versus placebo, both in combination with MTX, only the peficitinib 50 mg dose had a statistically significant difference in the ACR20 response at week 12 compared with placebo. In contrast to the 2 previous phase IIb studies with peficitinib (13, 15) , no dose-dependent ACR20 response was observed, although analysis of the DAS28 and the inflammatory markers, CRP and ESR, did suggest a dose-dependent response in the overall population.
Peficitinib in combination with MTX was well tolerated at all dose levels, with a safety profile similar to that observed in previous phase IIb trials of peficitinib (13, 15) .
In the current study, the ACR20 response rate in the placebo group was higher than anticipated, particularly in some regions of the world, and was in a range not evident in the 2 previous phase IIb studies of peficitinib. This response rate was considerably higher than the assumed placebo response rate of 30% in the sample size calculation. Analysis by region showed that the high placebo rate was predominantly attributed to Latin America and, unexpectedly, North America (which included only the US), with placebo response rates of 75% and 50%, respectively. Only in Europe, where the placebo response rate was in the expected range, was there a statistically significant difference between any peficitinib group and placebo in the ACR20 response rate, which is consistent with previous peficitinib phase IIb studies (13, 15) . Post hoc analyses excluding Latin America demonstrated a better dose-dependent ACR20 response, with both the peficitinib 50 mg and peficitinib 150 mg groups showing a statistically significant difference compared with placebo, driven mainly by a lower response rate in the placebo group as opposed to an increase in the response rate in any peficitinib group. Further analysis of the North America region showed a high response rate with placebo at 1 investigation site, which enrolled a substantial number of subjects (n 5 55; data not shown). Post hoc analyses excluding this site, although lowering the placebo response rate, were similar to analyses conducted in the overall population. This was because response rates in the peficitinib groups were also high; thus, exclusion of these subjects lowered the response rates in the peficitinib groups as well and therefore did not alter the overall interpretation of the results. It is not yet understood what the underlying factors were for the higher-than-expected placebo response rates experienced in Latin America and North America, but similarly high placebo response rates in Latin America have been reported in trials assessing anti-TNF treatments in RA (23) .
As with most clinical trials, this study had some limitations. Interpretation of the results needs to reflect the short duration and relatively small study size. To fully assess the efficacy and safety of peficitinib, longer-term and larger-scale phase III studies are currently ongoing (ClinicalTrials.gov identifiers: NCT02308163 and NCT02 305849) using the peficitinib 100-mg and 150-mg doses. In addition, as already discussed, the high placebo response rate is problematic for the accurate interpretation of peficitinib efficacy in this trial. Discussions are ongoing regarding the increasing placebo response rates observed across clinical trials over time (24) , which could represent a proxy for access to care. Further studies of peficitinib in treatment-resistant populations may be worth exploring in light of the lack of efficacy shown in this trial and the positive dose response seen in a phase II study in which ;50% of the population had been previously exposed to a biologic DMARD.
In conclusion, peficitinib has been shown in 2 phase IIb studies to be effective in reducing the symptoms of RA in patients with a prior inadequate response to DMARDs (13, 15) , demonstrating a dose-dependent response in the ACR20 and ACR50 response rates as well as a change from baseline in the DAS28-CRP. Although in this study a dose response was not observed for ACR20 responses, efficacy across multiple secondary end points was demonstrated with higher peficitinib doses. Peficitinib in combination with MTX was well tolerated, with a safety profile consistent with that observed in previous studies.
